Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Retained Earnings (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Retained Earnings for 11 consecutive years, with -$822.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 18.83% to -$822.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$822.4 million, a 18.83% decrease, with the full-year FY2025 number at -$822.4 million, down 18.83% from a year prior.
  • Retained Earnings was -$822.4 million for Q4 2025 at Cartesian Therapeutics, down from -$4.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$4.5 million in Q3 2022 to a low of -$822.4 million in Q4 2025.
  • A 5-year average of -$355.5 million and a median of -$413.1 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 14670.75% in 2024, then soared 99.33% in 2025.
  • Cartesian Therapeutics' Retained Earnings stood at -$430.3 million in 2021, then rose by 8.22% to -$394.9 million in 2022, then plummeted by 55.63% to -$614.6 million in 2023, then decreased by 12.6% to -$692.1 million in 2024, then fell by 18.83% to -$822.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Retained Earnings are -$822.4 million (Q4 2025), -$4.6 million (Q3 2025), and -$693.9 million (Q2 2025).